A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
for Multiple Myeloma
Drug: Daratumumab
17 locations incl. Scottsdale
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT07095452·Phase 2, Phase 3·Recruiting